
Frequency Therapeutics FREQ
Annual report 2025
added 03-12-2026
Frequency Therapeutics Accounts Receivables 2011-2026 | FREQ
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables Frequency Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 969 K | 1.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.7 M | 969 K | 1.33 M |
Quarterly Accounts Receivables Frequency Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 820 K | 1.09 M | 1.92 M | 1.7 M | 10 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 10 M | 820 K | 3.11 M |
Accounts Receivables of other stocks in the Biotechnology industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
I-Mab
IMAB
|
130 M | - | - | $ 866 M | ||
|
AbbVie
ABBV
|
12.6 B | $ 208.84 | -2.86 % | $ 369 B | ||
|
AbCellera Biologics
ABCL
|
39.4 M | $ 3.52 | 0.28 % | $ 1.05 B | ||
|
Acorda Therapeutics
ACOR
|
17.3 M | - | -24.86 % | $ 820 K | ||
|
Adverum Biotechnologies
ADVM
|
886 K | - | - | $ 86.2 M | ||
|
Advaxis
ADXS
|
234 K | - | -9.65 % | $ 45.9 M | ||
|
AgeX Therapeutics
AGE
|
57 K | - | -10.17 % | $ 12.2 K | ||
|
AIkido Pharma
AIKI
|
200 K | - | 1.93 % | $ 17.4 M | ||
|
Agenus
AGEN
|
1.83 M | $ 3.33 | -2.06 % | $ 99 M | ||
|
Alpine Immune Sciences
ALPN
|
392 K | - | - | $ 2.17 B | ||
|
Adaptive Biotechnologies Corporation
ADPT
|
50.4 M | $ 14.81 | 2.63 % | $ 2.25 B | ||
|
Altimmune
ALT
|
1.22 M | $ 3.34 | 7.05 % | $ 294 M | ||
|
Amgen
AMGN
|
9.57 B | $ 347.94 | -1.51 % | $ 187 B | ||
|
ANI Pharmaceuticals
ANIP
|
222 M | $ 74.21 | -2.3 % | $ 1.43 B | ||
|
Arcturus Therapeutics Holdings
ARCT
|
5.56 M | $ 8.03 | 2.29 % | $ 220 M | ||
|
Aurinia Pharmaceuticals
AUPH
|
41.5 M | $ 15.61 | 0.9 % | $ 2.1 B | ||
|
Autolus Therapeutics plc
AUTL
|
24 M | $ 1.41 | 2.17 % | $ 375 M | ||
|
Aptinyx
APTX
|
257 K | - | -39.0 % | $ 4.57 M | ||
|
Aytu BioScience
AYTU
|
31.2 M | $ 2.68 | 1.52 % | $ 16.8 M | ||
|
BioCryst Pharmaceuticals
BCRX
|
79.1 M | $ 9.02 | -3.84 % | $ 1.86 B | ||
|
Axon Enterprise
AXON
|
18.1 M | $ 412.81 | -2.54 % | $ 31.3 B | ||
|
Alnylam Pharmaceuticals
ALNY
|
778 M | $ 318.85 | -3.01 % | $ 41.8 B | ||
|
Ayala Pharmaceuticals
AYLA
|
234 K | - | - | $ 7.46 M |